Published Paper Details:

The International Conference on Harmonisation (ICH), the Food and Drug Administration of the United States (FDA), and the Canadian Drug and Health Agency (CDHA) are among the regulatory agencies that place a strong emphasis on the purity standards and the detection of impurities in active pharmaceutical ingredients (APIs). Reagents, heavy metals, ligands, catalysts, other substances like filter aids, charcoal, and the like, degraded end products obtained during or after manufacturing of bulk drugs from hydrolysis, photolytic cleavage, oxidative degradation, decarboxylation, enantiomeric impurity, and so on are just a few of the different sources of impurity in pharmaceutical products. Limits to permissible levels of impurities present in APIs or formulations are gradually being added by the various pharmacopoeias, including the British, American, andIndian versions.For example, capillary electrophoresis, electron paramagnetic resonance, gas-liquid chromatography, gravimetric analysis, high performance liquid chromatography, solid-phase extraction methods, liquid-liquid extraction methods, UV spectroscopy, infrared spectroscopy, supercritical fluid extraction column chromatography, mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, and others are used to isolate and characterise impurities in pharmaceuticals. Liquid chromatography (LC)-mass spectroscopy (MS), LCNMR, LC-NMR-MS, gas chromatography-mass spectroscopy (GC-MS), and LC-MS are the hyphenated methods used the most frequently for drug impurity profiling. This highlights the significance and necessity of drug impurity profiling in pharmaceutical research.